Enrolment completed in the MIV-711 osteoarthritis extension study and data monitoring committee recommendation to “Go Ahead”
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces continued progress towards the completion of its phase IIa program for the treatment of osteoarthritis: · The open label phase IIa extension study has completed enrollment · The independent Data Monitoring Committee (DMC) has recommended continuation of the extension study based on a review of the accumulated safety data The extension study of MIV-711 in patients with moderate knee osteoarthritis has now completed enrolment, having achieved its target of recruiting 50 patients. All patients in the extension